Austrália - inglês - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 2.5 mg) - tablet, uncoated - excipient ingredients: mannitol; calcium hydrogen phosphate dihydrate; maize starch; magnesium stearate - hypertension: for treatment of hypertension, lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: for treatment of heart failure, it is recommended that lisinopril be administered with a diuretic. acute myocardial infarction: for treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg, lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 20 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; magnesium stearate; iron oxide red - hypertension: pip-lisinopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: pip-lisinopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that pip-lisinopril tablets be administered with a diuretic. acute myocardial infarction: pip-lisinopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. pip-lisinopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; calcium hydrogen phosphate dihydrate; iron oxide red; maize starch; mannitol - hypertension: pip-lisinopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: pip-lisinopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that pip-lisinopril tablets be administered with a diuretic. acute myocardial infarction: pip-lisinopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. pip-lisinopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; magnesium stearate; maize starch; iron oxide red - hypertension: pip-lisinopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: pip-lisinopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that pip-lisinopril tablets be administered with a diuretic. acute myocardial infarction: pip-lisinopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. pip-lisinopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - lisinopril dihydrate (equivalent: lisinopril, qty 2.5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; magnesium stearate; mannitol; maize starch - hypertension: pip-lisinopril tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril (as dihydrate) in severe hypertension or renovascular hypertension. congestive heart failure: pip-lisinopril tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that pip-lisinopril tablets be administered with a diuretic. acute myocardial infarction: pip-lisinopril tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. pip-lisinopril tablets may be initiated within 24 hours of an acute myocardial infarction.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 10.89mg equivalent to 10 mg lisinopril;   - tablet - 10 mg - active: lisinopril dihydrate 10.89mg equivalent to 10 mg lisinopril   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide magnesium stearate mannitol pregelatinised maize starch starch - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 21.78mg equivalent to 20 mg lisinopril;   - tablet - 20 mg - active: lisinopril dihydrate 21.78mg equivalent to 20 mg lisinopril   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide pregelatinised maize starch magnesium stearate mannitol starch - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 5.445mg equivalent to 5.0 mg lisinopril;   - tablet - 5 mg - active: lisinopril dihydrate 5.445mg equivalent to 5.0 mg lisinopril   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide pregelatinised maize starch magnesium stearate mannitol starch - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

essential pharmaceuticals limited - lisinopril dihydrate - oral solution - 1 milligram(s)/millilitre - ace inhibitors, plain; lisinopril

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

taw pharma (ireland) ltd - lisinopril dihydrate - oral solution - ace inhibitors, plain; lisinopril